Stay updated on Pembrolizumab in Hodgkin Lymphoma: Frontline Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Hodgkin Lymphoma: Frontline Clinical Trial page.

Latest updates to the Pembrolizumab in Hodgkin Lymphoma: Frontline Clinical Trial page
- Check6 days agoChange DetectedThe government funding lapse notice on the ClinicalTrials.gov page has been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check28 days agoChange DetectedNo meaningful content changes were detected between the old and new screenshots; the study details, sections, and layout appear unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check49 days agoChange Detected- Added a government funding and operating-status notice and links to official sources; updated version to v3.2.0. - Removed the previous version tag v3.1.0.SummaryDifference3%

- Check57 days agoChange DetectedUpdate: revision version changed from v3.0.2 to v3.1.0, a metadata/branding update with no substantive content changes.SummaryDifference0.1%

- Check71 days agoChange DetectedPage updated to revision v3.0.2; the previous v3.0.1 tag was removed along with the Back to Top link. No substantive changes to core content or functional data.SummaryDifference0.2%

- Check78 days agoChange DetectedThe page has updated the status of the Peter MacCallum Cancer Centre, Australia, from 'Active, not recruiting' to 'Unknown status'. Additionally, the revision number has changed from v3.0.0 to v3.0.1.SummaryDifference0.9%

Stay in the know with updates to Pembrolizumab in Hodgkin Lymphoma: Frontline Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Hodgkin Lymphoma: Frontline Clinical Trial page.